Crystalline modifications and polymorphism changes during drug manufacture;Modifications cristallines et transformations polymorphes au cours des opérations galéniques

Annales Pharmaceutiques Francaises

Volumn 60, Issue 3, 2002, Pages 161-176

  Doelker, E ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Adsorbates; Amorphisation; Complexes; Dissolution; Freeze drying; Granulation; Grinding; Milling; Polymorphic transformations; Spray drying; Stability; Tabletting

Indexed keywords

ACETYLSALICYLIC ACID; ASPARTAME; BETA CYCLODEXTRIN; CAFFEINE; CARBAMAZEPINE; CEFALEXIN; CEFALOTIN; CEFIXIME; CHLORAMPHENICOL PALMITATE; CHLORPROPAMIDE; CIMETIDINE; COLECALCIFEROL; CYCLOPHOSPHAMIDE; ESTRADIOL; GRISEOFULVIN; INDOMETACIN; LACTOSE; MANNITOL; PARACETAMOL; PHENOBARBITAL; PHENYLBUTAZONE; PIROXICAM; POVIDONE; PROBUCOL; SALBUTAMOL SULFATE; SUCROSE; SULFATHIAZOLE; TREHALOSE;

ADSORPTION; CRYSTALLIZATION; DRUG GRANULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; GRINDING; MOLECULAR DYNAMICS; NEBULIZATION; REVIEW; TABLET COMPRESSION; TABLET MANUFACTURE;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG COMPOUNDING; DRUG INDUSTRY; ISOMERISM; PHARMACEUTICAL PREPARATIONS;

EID: 18244431798     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Polymorphie bei Arzneimitteln
2. The status and future of chemical microscopy
3. Pharmaceutical applications of polymorphism
4. Classification of non-crystalline solids
5. Polymorphisme des médicaments et activité thérapeutique
6. Polymorphic von arzneistoffen und ihre bedeutung in der pharmazeutischen technologie
7. Characterization of habits and crystalline modification of solids and their pharmaceutical applications
8. Polymorphie bei arzneistoffen
9. Le polymorphisme des substances organiques médicamenteuses
10. Le polymorphisme
11. The relevance of polymorphism
12. Introduction au Polymorphisme
13. Le polymorphisme: Sa détection et son incidence sur la dissolution
14. Polymorphism in drug design and delivery
15. Prüfung von kristallformen der wirkstoffe. Metastabile kristallformen und flüssiger arzneizubereitungen
16. Review of crystal polymorphism of substances in the European Pharmacopoeia
17. Solid-state pharmaceutical chemistry
18. Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates
19. Crystal polymorphism and related phenomena of substances in the European Phamacopoeia. An updated review for fasciculae 13 to 19. Part 2
20. Analysis of organic polymorphs. A review
21. Spectral Methods for the characterization of polymorphic and solvates
22. Polymorphie und thermische analyse pharmazeutischer wirkstoffe
23. Étude du poly morphisme et du pseudopolymorphisme à l'aide de méthodes thermo-analytiques. Rapport d'une commission SFSTP
24. Le polymorphisme, son origine, ses caractéristiques, ses conséquences dans le domaine pharmaceutique
25. Caractères physicochimiques des principes actifs. Leurs conséquences sur la faisabilité et la stabilité des formes galéniques
26. Polymorphie von arzneistoffen. Eine wirstschaftliche herausforderung?
27. Polymorphic transformations of some drugs under compression
28. Molekulargalenik als grundlage moderner arzneiformung
29. Molecular pharmaceutics
30. New concepts in pharmaceutics
31. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state
32. Glassy state of pharmaceuticals. III. Thermal properties and stability of glassy pharmaceuticals and their binary glass systems
33. Molecular mobility of the paracetamol amorphous form
34. Effects of sorbed water on the crystallization of indomethacin from the amorphous state
35. Solid-state studies of mannitol and mannitol-sorbitol mixtures
36. Non-isothermal and isothermal crystallization of sucrose from the amorphous state
37. The relationship between the glass transition temperature and water vapor absorption by poly(vinylpyrrolidone)
38. What is the true solubility advantage for amorphous pharmaceuticals?
39. Effect of grinding on the transformations of polymorphs of chloramphenicol palmitate
40. Effect of seed crystals on solid-state transformation of polymorphs of chloramphenicol palmitate during grinding
41. Polymorphic transitions of cimetidine during manufacture of solid dosage forms
42. Glassy state of pharmaceuticals 11. Bioinequivalence of glassy and crystalline indomethacin
43. Increased metastable solubility of milled griseofulvin, depending on the formation of a disordered surface structure
44. Amorphous content determination in semicrystalline mixtures using diffuse reflectance near-infrared spectroscopy
45. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability
46. Effects of environmental temperature and compression energy on polymorphic transformation during tabletting
47. Polymorphic transformation of sulfabenzamide under tabletting. Influence of excipients and consequent dissolution properties
48. Changes in solid-state structure of cyclophosphamide monohydrate induced by mechanical treatment and storage
49. Pharmaceutical hydrates
50. Kinetics of transition of anhydrous carbamazepine to carbamazepine dihydrate in aqueous suspensions
51. Crystal growth studies involving phase transitions in aqueous drug suspensions
52. Hydrate formation of metronidazole benzoate in aqueous suspensions
53. Inclusion complexation of metronidazole benzoate with β-cyclodextrin and its depression of anhydrate-hydrate transition in aqueous suspensions
54. Some pharmaceutical properties of novobiocin
55. Polymorphism and desolvation of flupirtine maleate
56. Examination of the polymorphism of piroxicam in connection with the preparation of a new «soft-patch» type pharmaceutical dosage form
57. Étude des transformations polymorphiques du sulfanilamide au cours de la fabrication de comprimés
58. Effect of solvate formation on lyoavailability of lorazepam during wet granulation
59. Instability of drug release from anhydrous theophylline-microcrystalline cellulose formations
60. Effect of polymorphic transformation during the extrusion-granulation process on the pharmaceutical properties of carbamazepine granules
61. Effect of polymorphic forms of bulk powders on pharmaceutical properties of carbamazepine granules
62. Polymorphism in anhydrous theophylline-Implications on the dissolution rate of theophylline tablets
63. Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior
64. Zur polymorphic oraler antidiabetica. 2. Mitt. Tolbutamid
65. Characterization and interconversion of polymorphs of premafloxacin, a new quinolone antibiotic
66. Hydration and dehydration behavior of aspartame hemihydrate
67. Nachhärtung und zerfallscharakteristik bei tabletten aus metastabilen polymorphen modifikationen (meprobamat)
68. Zur zeitabhängigkeit der modifikationsumwandlung des sulfanilamids bei der tablettenkompression
69. Evaluation of crystallinity and drug release stability of directly compressed theophylline hydrophilic matrix tablets stored under varied moisture conditions
70. More information on hardening of carbamazepine tablets
71. Physicochemical characterization of spray-dried phenylbutazone polymorphs
72. Sprühtrocknung polymorpher arzneistoffe
73. Polymorphism and stability of norfloxacin, (1-Ethyl)-6-Fluoro-1,4-dihydro-4-oxo-7-(1-Piperazinil)-3-Quinolinocarboxylic acid
74. th meeting of supercritical fluid
75. Pure paracetamol for direct compression. Part I. Development of sintered-like crystals of paracetamol
76. Pure paracetamol for direct compression. Part II. Study of the physicochemical and mechanical properties of sintered-like crystals of paracetamol
77. A new pure paracetamol for direct compression: The orthorhombic form
78. Characterization of phase transitions during freeze-drying by in situ x-ray powder diffractometry
79. Rational design of stable lyophilized protein formulations: Some practical advice
80. Glycine crystallization during freezing: The effects of salt form, pH, and ionic strength
81. Physical and chemical changes of medicinals in mixtures with adsorbents in the solid state. IV: Study on reduced-pressure mixing for practical use of amorphous mixtures of flufenamic acid
82. Use of adsorbents in enhancement of drug dissolution II
83. Isolation and solid-state characteristics of a new crystal form of indomethacin
84. Polymorphic transitions of indomethacin in the preparation of indomethacin/haemodex sorbates
85. Crystallization and polymorphic transition behavior of chloramphenicol palmitate in 2-hydroxypropyl-cyclodextrin matrix
86. Pharmaceutical solids: A strategic approach to regulatory considerations
87. Le guideline ICH-Q6A